Beta57% was sold under disclosed trading plans, 29% to cover taxes, 14% with no plan disclosed. The largest seller, Serge Saxonov (Chief Executive Officer, Director), sold $6.8M.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
A share of stake is shown for 0 of the 6 officers and directors who sold. 9 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Serge Saxonov, Benjamin Hindson, John Stuelpnagel, Adam Taich, Alan Mateo, Sridhar Kosaraju, Sarah Teichmann, Shehnaaz Suliman and Kimberly Popovits (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Serge Saxonov Chief Executive Officer, Director | 25,000 | $81.22 | n/a | n/a | Sep 22, 2026 | Sep 24, 2026 |
| Shehnaaz Suliman Director | 5,723 | $81.19 | n/a | n/a | Sep 22, 2026 | Sep 24, 2026 |
"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
Yes. Serge Saxonov sold 172K shares ($6.8M) in the past 12 months, 77% of it under a trading plan disclosed in the filings.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 57% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 29% were to cover taxes and 14% had no disclosed plan. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Serge Saxonov Chief Executive Officer, Director | $6.8M 172K shares | Not confirmedshare of stake is being verified. Why | 77% under a disclosed plan, 23% to cover taxes |
| Adam Taich Chief Financial Officer | $4.8M 100K shares | Not confirmedshare of stake is being verified. Why | 62% under a disclosed plan, 38% to cover taxes |
| John Stuelpnagel Director | $2.4M 40K shares | Not confirmedshare of stake is being verified. Why | No plan disclosed |
| Benjamin Hindson President and Chief Scientific Officer, Director | $1.5M 42K shares | Not confirmedshare of stake is being verified. Why | To cover taxes |
| Shehnaaz Suliman Director | $792K 14K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Sarah Teichmann Director | $579K 15K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 16, 2025 | Sold | Held Oct 16, 2026 | Still held | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Serge Saxonov!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Serge Saxonov are complete. Chief Executive Officer, Director | n/a | −172K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Serge SaxonovHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Serge Saxonov are complete; balances and unit counts will be added when the check is finished. −6.8Kgifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($82.28 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close. | ||||||||||||
Benjamin Hindson!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Benjamin Hindson are complete. President and Chief Scientific Officer, Director | n/a | −42K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Benjamin HindsonHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin Hindson are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($82.28 − strike price), using the most recent insider trade price on Form 4 (Sep 22, 2026), not a market close. | ||||||||||||
John Stuelpnagel!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for John Stuelpnagel are complete. Director | n/a | −40K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for John StuelpnagelHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Stuelpnagel are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Adam Taich!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Adam Taich are complete. Chief Financial Officer | n/a | −100K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Adam TaichHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adam Taich are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Alan Mateo!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alan Mateo are complete. Director | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Alan MateoHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alan Mateo are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Sridhar Kosaraju!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sridhar Kosaraju are complete. Director | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Sridhar KosarajuHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sridhar Kosaraju are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Sarah Teichmann!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Sarah Teichmann are complete. Director | n/a | −15K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Sarah TeichmannHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sarah Teichmann are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Shehnaaz Suliman!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Shehnaaz Suliman are complete. Director | n/a | −14K | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Shehnaaz SulimanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Shehnaaz Suliman are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Kimberly Popovits!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kimberly Popovits are complete. Director | n/a | 0 | n/a | n/a | ||||||||
Vesting, gifts, unvested awards and holding lines for Kimberly PopovitsHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kimberly Popovits are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||
Holdings and share of stake for 10x Genomics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $16.9M across 381,782 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($7.3M), including tax-related sales outside a plan.
Sales with no 10b5-1 plan and no tax reference in the filing. $2.4M of it is John Stuelpnagel. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: John Stuelpnagel, Aug 11, 2026
$5.3M of sales (31.7%) cite tax obligations in their footnotes, $444K of them also under a plan. Example: Adam Taich, Aug 24, 2026
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Serge Saxonov Chief Executive Officer, Director | 172K | $6.8M | 77% | 40% | Nov 24, 2025 to Sep 22, 2026 |
| Adam Taich Chief Financial Officer | 100K | $4.8M | 62% | 29% | Nov 24, 2025 to Sep 9, 2026 |
| John Stuelpnagel Director | 40K | $2.4M | 0% | 14% | Aug 11, 2026 to Sep 3, 2026 |
| Benjamin Hindson President and Chief Scientific Officer, Director | 42K | $1.5M | 0% | 9% | Nov 24, 2025 to Aug 24, 2026 |
| Shehnaaz Suliman Director | 14K | $792K | 100% | 5% | Jun 16, 2026 to Sep 22, 2026 |
| Sarah Teichmann Director | 15K | $579K | 100% | 3% | Feb 25, 2026 to Aug 14, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $635K | $0 | $635K | $0 |
| Dec 2025 | $0 | $0 | $0 | $0 |
| Jan 2026 | $0 | $0 | $0 | $0 |
| Feb 2026 | $638K | $147K | $491K | $0 |
| Mar 2026 | $656K | $656K | $0 | $0 |
| Apr 2026 | $123K | $123K | $0 | $0 |
| May 2026 | $1.4M | $709K | $652K | $0 |
| Jun 2026 | $1.2M | $1.2M | $0 | $0 |
| Jul 2026 | $0 | $0 | $0 | $0 |
| Aug 2026 | $5.5M | $1.2M | $3.1M | $1.2M |
| Sep 2026 | $6.7M | $5.5M | $0 | $1.2M |
| Oct 2026 | $0 | $0 | $0 | $0 |
In line with the past 5 years. 6 insiders sold; the average is 5 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 16, 2026 Latest 12 months | 382K | 6 | $16.9M |
| Oct 16, 2025 1 year earlier | 90K | 3 | $1.1M |
| Oct 16, 2024 2 years earlier | 83K | 4 | $3.1M |
| Oct 17, 2023 3 years earlier | 157K | 6 | $8.5M |
| Oct 17, 2022 4 years earlier | 323K | 6 | $45.6M |
| Oct 17, 2021 5 years earlier | 1.12M | 6 | $187M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for 10x Genomics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 407 Forms 3, 4 and 5 on record for 10x Genomics, Inc. (SEC CIK 1770787), filed from Sep 11, 2019 to Sep 24, 2026; 38 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
| Name | Last filed | Last reported balance |
|---|---|---|
| Justin McAnear | Aug 26, 2024 | 143,242 shares, last reported balance as of Aug 22, 2024 |
| Mathai Mammen | Jun 13, 2024 | 180,259 shares, last reported balance as of Jun 11, 2024 |
| James Wilbur | Nov 27, 2023 | 83,342 shares, last reported balance as of Nov 22, 2023 |
| Bryan Roberts | Jun 16, 2023 | 10,680,972 shares, last reported balance as of Jun 14, 2023 |
| Bryan Roberts | Jun 16, 2023 | 4,466,266 shares, last reported balance as of Jun 14, 2023 |
| Bradford Crutchfield | May 25, 2022 | 97,237 shares, last reported balance as of May 23, 2022 |
| Paladin Capital Management, LLC | Feb 1, 2021 | 20,910,901 shares, last reported balance as of Apr 30, 2020 |
| Venrock Associates VI, L.P. | Dec 10, 2020 | 12,567,566 shares, last reported balance as of Dec 10, 2020 |
| Foresite Capital Management I, LLC | May 14, 2020 | 11,761,109 shares, last reported balance as of May 13, 2020 |
| SOFTBANK VISION FUND (AIV M2) L.P. | Mar 18, 2020 | 3,836,232 shares, last reported balance as of Feb 19, 2020 |
| Paul Conley | Sep 12, 2019 | No balance on record |
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.